EMAP-II in metabolic syndrome

Abstract

The objective: тo determine the serum level of EMAP-II as a marker of endothelial dysfunction in patients with metabolic syndrome, to study its relationship with the other risk factors for cardiovascular disease.Materials and methods. We examined 23 patients with WHO criteria of metabolic syndrome, 30 patient with ATP III criteria of metabolic syndrome, 18 – IDF criteria, 22 healthy control subjects. The content of EMAP-II was determined by an enzyme immunoassay using the Amprer column (Amersham Lifesilence) and the Amersham pharmacia biotech test system (England). Serum levels of EMAP-II were determined by immunoenzyme assay. The data were presented as means±SD. Statistical analysis was performed using the Student test, Person rank correlation coefficient.Results. We found an increased serum level of EMAP-II in patients with WHO, ATP III, IDF criteria of metabolic syndrome compared to control group (4,22±1,96 ng/ml, 3,95±2,04 ng/ml, 3,92±2,04 ng/ml and 1,46±0,65 ng/ml respectively; р<0,05). Also, the level of EMAP-II correlated with key markers of insulin resistance, carbohydrate and lipid metabolism (p<0,05).Conclusion. The revealed changes of EMAP-II serum levels could reflect an endothelial dysfunction in patients with metabolic syndrome. Insulin resistance, hyperglycaemia, dyslipidemia appear to be significant contributing factor to the elevation of EMAP-II.